These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 22398664

  • 1. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.
    Xiang Q, Cui YM, Zhao X, Yan L, Zhou Y.
    Pharmacology; 2012; 89(1-2):105-10. PubMed ID: 22398664
    [Abstract] [Full Text] [Related]

  • 2. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ.
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [Abstract] [Full Text] [Related]

  • 3. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [Abstract] [Full Text] [Related]

  • 4. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
    He J, Qiu Z, Li N, Yu Y, Lu Y, Han D, Li T, Zhao D, Sun W, Fang F, Zheng J, Fan H, Chen X.
    Eur J Clin Pharmacol; 2011 Jul; 67(7):701-7. PubMed ID: 21327909
    [Abstract] [Full Text] [Related]

  • 5. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q, Chen QX, Ruan ZR, Yuan H, Xu HM, Zeng S.
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [Abstract] [Full Text] [Related]

  • 6. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers.
    Xu P, Jiang ZP, Zhang BK, Tu JY, Li HD.
    Pharmacology; 2008 Mar; 82(3):221-7. PubMed ID: 18810246
    [Abstract] [Full Text] [Related]

  • 7. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
    Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M.
    J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
    [Abstract] [Full Text] [Related]

  • 8. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males.
    Zhang Y, Jiang XH, Hu YQ, Li ZR, Su L, Wang ZG, Ma G.
    Br J Clin Pharmacol; 2008 Aug; 66(2):247-54. PubMed ID: 18460034
    [Abstract] [Full Text] [Related]

  • 9. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
    Zhou Q, Ruan ZR, Yuan H, Zeng S.
    Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809
    [Abstract] [Full Text] [Related]

  • 10. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
    Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ.
    Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
    [Abstract] [Full Text] [Related]

  • 11. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM.
    J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
    [Abstract] [Full Text] [Related]

  • 12. CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.
    Ruzilawati AB, Gan SH.
    Pharmacology; 2010 Jun; 85(6):357-64. PubMed ID: 20523106
    [Abstract] [Full Text] [Related]

  • 13. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T, Hisaka A, Sugiyama Y, Ito K.
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [Abstract] [Full Text] [Related]

  • 14. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
    Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M.
    Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
    [Abstract] [Full Text] [Related]

  • 15. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
    Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M.
    Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
    [Abstract] [Full Text] [Related]

  • 16. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males.
    Zhang WX, Chen GL, Zhang W, Tan ZR, Liu J, Zhou G, Hu DL, Zhou HH.
    Clin Chim Acta; 2005 Sep; 359(1-2):46-52. PubMed ID: 16170863
    [Abstract] [Full Text] [Related]

  • 17. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
    Bidstrup TB, Damkier P, Olsen AK, Ekblom M, Karlsson A, Brøsen K.
    Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
    [Abstract] [Full Text] [Related]

  • 18. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q, Ruan ZR, Jiang B, Yuan H, Zeng S.
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [Abstract] [Full Text] [Related]

  • 19. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.
    Gertz M, Tsamandouras N, Säll C, Houston JB, Galetin A.
    Pharm Res; 2014 Sep; 31(9):2367-82. PubMed ID: 24623479
    [Abstract] [Full Text] [Related]

  • 20. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
    Pei Q, Liu JY, Yin JY, Yang GP, Liu SK, Zheng Y, Xie P, Guo CX, Luo M, Zhou HH, Li X, Liu ZQ.
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1021-1028. PubMed ID: 29748863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.